A Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate
the safety and efficacy of FMX103 topical foam containing 1.5% minocycline compared to
vehicle, in the treatment of subjects with moderate-to-severe facial papulopustular rosacea.
Qualified subjects will be randomized to receive 1 of the following 2 treatments:

- FMX103 minocycline foam 1.5%

- Vehicle foam

Inclusion Criteria:

1. Moderate-to-severe rosacea (as per the IGA score; Table 3) on the proposed facial
treatment area consisting of:

1. At least 15 and not more than 75 facial papules and pustules, excluding lesions
involving the eyes and scalp;

2. No more than 2 nodules on the face.

2. Presence of or history of erythema and/or flushing on the face.

Exclusion Criteria:

1. Presence of any skin condition and/or Excessive facial hair, on the face that would
interfere with the diagnosis or assessment of rosacea.

2. Moderate or severe rhinophyma, dense telangiectasia (score 3, severe), or plaque-like
facial edema.

3. History of hypersensitivity or allergy to minocycline, any other tetracycline, or of
any other component of the formulation.

4. Active ocular rosacea (eg, conjunctivitis, blepharitis, or keratitis) of sufficient
severity to require topical or systemic antibiotics.